About AtoCap

AtoCap’s team combines world-class academic, clinical and commercialisation expertise and has a strong track of record of successfully translating highly innovative technologies into commercial opportunities that generate substantive income and impact endpoints for stakeholders and investors.

The team initially developed from within University College London’s Encapsulation Research Group and is based on a novel implementation of electro-hydrodynamic processing for the preparation of a wide range of encapsulated structures via a clean, efficient, one step route.

Our Technology

Microencapsulation: AtoCap Technology enables the encapsulation of patient- specific combinations of generic drugs such as antibiotics and chemotherapeutics into a multi-layered capsule.

Our first product ‘CapFuran’ enables time-release killing of patient-derived uropathogenic E. Coli cultures by a well known and frequently used generic antibiotic with and without encapsulation in AtoCap capsules.

Targeted and Penetrative Delivery: The capsules can be delivered by a single, minimally invasive outpatient procedure.

The multi-layered capsule formulation allows for both immediate and sustained release of the drug precisely where it is required.

Flexible and Versatile: The capsules can be adapted to deliver multiple other drug cargos to treat a variety of clinical needs.

Clinical Application

The principal area of clinical application the business is currently focussed on is targeted antibiotic delivery for chronic urinary tract infections (UTI). UTI is one of the most common infectious diseases worldwide, affecting over 10 million patients per year globally and particularly the growing elderly population.

  • It can be a particular problem in other vulnerable patient groups such as pregnant women, people with multiple sclerosis or spinal injury, in kidney transplant patients and in anyone requiring a urinary catheter.
  • Most common hospital-acquired infections, adding extra costs, complications and bed-days to patients suffering from other causes.
  • Often low-grade and recurring, causing much morbidity including kidney infection, sepsis and some mortality.
  • Low-grade UTI are difficult to diagnose and treat.
  • Caused by multiple species of bacteria, often in combination.
  • Often can invade cells and persist in intracellular reservoirs or biofilms, which are resistant to antibiotics and the immune system, leading to recurrences or recalcitrance.

AtoCap’s development of penetrating nano-or microcapsules may offer a solution to all of these problems – introduced directly into the bladder in a simple, painless outpatient procedure. It offers a unique way to repurpose already-approved therapeutics for a renewed utility.

The current approach to systemic antibiotic treatment is fraught with limitations:

  • Bacterial intracellular invasion and possible biofilm formation cans complicate treatment.
  • It is difficult to get high local doses in the bladder (many drugs are metabolized before this point) and without incurring systemic side effects.
  • Treatment may need to be prolonged, increasing the risk of antibiotic resistance.